|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Departments of Lymphoma-Myeloma,
Hematopathology, and Molecular Pathology, University of Texas M. D. Anderson Cancer Center, Houston; First Department of Internal
Medicine and Laboratory of Histology and Embryology, National and
Kapodistrian University of Athens, Greece; Departments of Medical
Oncology and Pathology, Istituto Nazionale Tumori, Milan, Italy; and
Departments of Hematology and Pathology, University of Verona, Italy.
To determine the clinical significance of BCL-2 expression in
Hodgkin-Reed-Sternberg (HRS) cells of classical Hodgkin disease (cHD),
we correlated its expression with presenting clinical and laboratory
features and failure-free survival (FFS). Eligible patients were
untreated and negative for HIV-1; they had biopsy-proven cHD.
BCL-2 expression was determined immunohistochemically in available
pretreatment tissue biopsy specimens without knowledge of clinical
outcome. Tumors were considered positive if any HRS cells expressed
BCL-2. We identified 707 patients with cHD, whose median age was 30 years; 54% were men. HRS cells expressed BCL-2 in 359 (65%) of 551 nodular sclerosis, 67 (47%) of 143 mixed cellularity, and all 5 lymphocyte depletion. For all patients, the 5-year FFS was 74% versus
84% for tumors with versus without BCL-2 expression (P = .0016, by log-rank test). For the 412 patients
treated with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD)
or equivalent regimens, the 5-year FFS for tumors with versus without BCL-2 expression was 74% versus 88% (P = .001, by
log-rank test); for the 233 patients with Ann Arbor stage I or II, FFS
was 84% versus 92% (P = .04, by log-rank test); and for
the 179 patients with Ann Arbor stage III or IV, FFS was 62% versus
81% (P = .006, by log-rank test). Multivariate analysis
confirmed that BCL-2 expression is independently associated with
inferior FFS along with age 45 or older, Ann Arbor stage IV, low serum
albumin and high serum lactate dehydrogenase levels. We conclude that
BCL-2 is frequently expressed by HRS cells in cHD and is associated with inferior FFS in patients treated with ABVD or equivalent regimens.
(Blood. 2002;100:3935-3941) Even though Hodgkin disease (HD) is curable,
approximately 30% of all patients relapse and eventually die of
progressive disease or complications of therapy.1 Several
clinical and laboratory features have been used to predict failure-free
survival (FFS) and overall survival (OS) to adjust therapy according to
the predicted risk of relapse. These features include age,
sex, bulky peripheral or mediastinal disease, Ann Arbor
stage IV, bone marrow or inguinal lymph node involvement,
anemia, leukocytosis, lymphocytopenia, low serum levels of albumin,
high serum levels of lactate dehydrogenase (LDH) or
Immunologic and molecular studies have shown that in classical HD
(cHD) most Hodgkin and Reed-Sternberg (HRS) cells are derived from
germinal center B cells with rearranged immunoglobulin genes but
without cell surface expression of B-cell receptor.11,12 This has been attributed by some investigators to crippling
mutations11,13 and by others to transcriptional defects of
the rearranged immunoglobulin genes in HRS cells.14,15
Either mechanism would preclude the expression of functional B-cell
receptor on the surface of HRS cells, which would be expected to induce
apoptosis in normal germinal center cells. However, HRS cells escape
apoptotic death despite no functional B-cell receptor, and the
underlying salvage mechanisms for their escape are not yet known.
BCL2, first identified by its involvement in the
t(14;18)(q32;q21) characteristic of follicular
lymphomas,16 is a major negative regulator of apoptosis.
The t(14;18) results in overexpression of BCL-2 protein and represents
the first example of oncogenesis mediated by decreased cell
death.17,18 The mechanism of the antiapoptotic function of
BCL-2 is only partially understood, involving decreased mitochondrial
release of cytochrome c, which is, in turn, required for
procaspase-9 activation and initiation of the apoptotic
cascade.19
Previous studies have shown that HRS cells express BCL-2 mRNA and
protein20-22 even though they lack
t(14;18)(q32;q31).23-25 The expression of BCL-2 by HRS
cells may prevent apoptosis caused by the absence of functional B-cell
receptor and, thus, explain tumorigenesis. In addition, BCL-2
expression may explain resistance to treatment-induced apoptosis of HRS
cells and eventual clinical treatment failure. However, the clinical
significance of BCL-2 expression in uniformly treated patients with cHD
remains undefined.
Therefore, we decided to determine BCL-2 expression in HRS cells of
previously untreated patients with cHD and correlate its expression
with presenting clinical and laboratory features and clinical outcome.
We used FFS as the primary end point, censoring all events other than
tumor progression. However, we also examined OS. To minimize the effect
of regimens with different efficacy, we also analyzed FFS and OS of
patients treated with adriamycin, bleomycin, vinblastine, and
dacarbazine (ABVD) or equivalent regimens. Our findings demonstrate
that BCL-2 expression in HRS cells of cHD is an adverse biologic
prognostic factor for FFS and OS and suggest that modulation of BCL-2
function may have future therapeutic implications.
Patients
Staging
Therapy Treatment was either standard or according to investigational protocols that were active during the time the patient was diagnosed at the participating institutions. Informed consent (signed or oral) was obtained before all procedures and before the administration of all investigational therapy according to local practice guidelines.Regimens included nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP)28 in 61 patients; doxorubicin or epirubicin, bleomycin, vinblastine, and dacarbazine (ABVD or EBVD)29,30 in 224; MOPP alternating with ABVD1,31 in 101; cyclophosphamide, vinblastine, prednisone, procarbazine (CVPP) alternating with doxorubicin, bleomycin, dacarbazine, prednisone, and carmustine (ABDIC)32 in 69; vinblastine, etoposide, prednisone, epirubicin, and bleomycin (VEBEP)33 in 18; and mitoxantrone, vincristine, vinblastine, and prednisone (NOVP) followed by variable radiotherapy ports32 in 157 patients. Radiotherapy was administered after completion of chemotherapy in 464 patients with various ports and dosages according to local standard or investigational protocols. Fifty-nine highly selected patients with perceived favorable prognosis were treated only with curative radiotherapy according to the policies of each center. For the purposes of this analysis ABVD, EBVD, CVPP/ABDIC, and MOPP/ABVD were considered equivalent regimens.1,34,35 Kaplan-Meier analysis also revealed that patients treated with VEBEP had identical FFS with those treated with ABVD. This was confirmed by multivariate analysis adjusting for other prognostic features, in which VEBEP was not statistically different from ABVD (data not shown). Therefore, for the purposes of the present analysis, VEBEP was also considered equivalent to ABVD. Complete remission (CR) was defined as absence of disease for at least 1 month as determined by physical examination and appropriate laboratory and imaging studies. Partial remission (PR) was defined as more than 50% reduction of tumor load, estimated as the sum of the products of 2 perpendicular diameters of all measurable lesions. Progressive disease (PD) was defined as more than 25% reduction of tumor load or development of disease in a previously uninvolved site. Primary treatment failure was defined as failure to achieve CR or PR during initial therapy. Relapse was defined as progression occurring at least 1 month after CR or PR. Immunohistochemistry Method. The immunohistochemical method used to detect BCL-2 expression in HRS cells has been described previously.36 Tissue sections were deparaffinized in xylene and rehydrated in a graded series of ethanols. Endogenous peroxidase was blocked by 3% hydrogen peroxide in 140 mM NaCl, 2 mM KCl, 12 mM NaPO4, 1.7 mM KH2PO4, pH 7.4 (phosphate-buffered saline [PBS]) for 10 minutes at room temperature. Heat-induced epitope retrieval and a monoclonal antibody specific for BCL-2 (clone 124, Dako, Carpinteria, CA) in a dilution of 1:50 were used.36 Each reaction set included external controls that were a BCL-2+ follicular lymphoma, and a cell block of K562 cells, which do not express BCL-2. In addition, coexisting reactive lymphocytes served as internal positive and negative controls in each slide. Evaluation. Evaluation of all slides was performed by 2 hematopathologists (G.Z.R. and L.J.M.) without knowledge of the clinical outcome. All slides were reviewed at the time of immunohistochemical analysis for confirmation of the diagnosis of cHD according to criteria outlined by the WHO classification.26 Slides were considered evaluable for BCL-2 if all concurrent internal and external immunohistochemistry controls stained appropriately. Any cytoplasmic BCL-2 staining of HRS cells was considered positive, based on the assumption that even few cells expressing BCL-2 might be resistant to therapy-induced apoptosis and thus cause clinical relapse. At least 100 HRS cells in representative fields were counted in each tumor to determine the percentage of HRS cells expressing BCL-2. Staining intensity was considered as absent, when no HRS cells expressed BCL-2; weak, when HRS cells stained for BCL-2 less intensely than the small reactive lymphocytes; and strong, when HRS cells stained for BCL-2 with equal or greater intensity than small reactive lymphocytes. Statistical analysis Failure-free survival (FFS) was measured from the beginning of treatment to primary treatment failure, relapse, or last follow-up. Patients who died during treatment without evidence of PD or after the end of therapy without prior evidence of relapse were censored at the time of these events. This censoring was also used by Hasenclever and Diehl, in their development of the IPS.5 Its purpose is to eliminate the confounding effect of deaths from neutropenia, second malignancies, cardiac or pulmonary complications of treatment, and other causes that do not provide insight in the biology of the disease. OS was measured from the beginning of treatment to the time of last follow-up or death from any cause. Actuarial survival was measured by the method of Kaplan and Meier.37 The statistical significance of differences in FFS between groups of patients was estimated by the log-rank test.38 The statistical independence between prognostic variables was evaluated by multivariate analysis using the Cox proportional hazards model.39 The comparisons between BCL-2 expression and presenting clinical and laboratory features were based on 2 and Fisher exact
tests, as appropriate. The nonparametric Mann-Whitney test was used to
evaluate the correlation between patient age and BCL-2 expression. All
statistical calculations were performed using StatView (Abacus
Concepts, Berkeley, CA).
Study group We identified 1695 untreated patients with cHD in the participating institutions between 1984 and 2001. Archival pretreatment biopsy material was available for 707 patients who constitute the study group with known BCL-2 expression status. Most presenting clinical and laboratory features of patients with known versus unknown BCL-2 expression are similar (Table 1). However, patients with known BCL-2 status were more likely to have higher serum 2-microglobulin levels than those without
available tissue, but the difference was marginally significant
(P = .04, by Fisher exact test; Table 1). Therefore, we
consider the analyzed group to be representative of the whole patient
population. The histologic types of cHD in this study group were
nodular sclerosis in 551, mixed cellularity in 143, lymphocyte
depletion in 5 patients, and cHD not further classified in 8 patients.
BCL-2 expression BCL-2 was detected in HRS cells of 433 (61%) of 707 cHD tumors (Table 2), where it was present in the cytoplasm of HRS cells with variable staining intensity. Reactive small lymphocytes, present in variable numbers in all tumors, were strongly positive for BCL-2 and served as internal positive controls (Figure 1).
The mean percentage of BCL-2+ HRS cells (mean ± SD)
was 74.3% ± 17% and ranged from 15% to 100% (median, 80%). In
most positive tumors, BCL-2 was detected in the majority of HRS cells
(Figure 2A). However, the intensity of
BCL-2 staining in HRS cells was more variable among tumors, and
expression was weak in 36% and strong in 25% (Table 2 and Figure 2B).
Strong intensity of BCL-2 staining was associated with expression in a
high fraction of HRS cells (P < .0001 by Mann-Whitney
test).
The frequency of BCL-2 staining intensity in histologic types of HD is
shown in Table 2. BCL-2 expression was more frequent (65% versus 47%;
P < .0001 by Fisher exact test) and stronger in nodular
sclerosis (27% versus 16%; P = .0006 by
Survival analysis In the entire study group of 707 patients, the 5-year FFS was 74% for tumors with BCL-2-positive HRS cells compared with 84% for tumors with HRS cells negative for BCL-2 (P = .0016 by log-rank test). Treatment was with ABVD or equivalent regimens in 412 patients and various other approaches for the remaining 295 patients. Therefore, a more detailed analysis for FFS and OS was performed using the 412 patients treated with ABVD or equivalent regimens, to eliminate the confounding effects of treatments of variable efficacy.After a median follow-up of 83 months for survivors, 85 (21%) of the
412 patients treated with ABVD or equivalent regimens had refractory
disease or relapsed after an initial CR or PR. The 5-year FFS for
patients with cHD with BCL-2+ versus BCL-2
At 5 years, OS for patients with cHD with BCL-2+ versus
BCL-2 The intensity of BCL-2 staining in HRS cells also correlated with FFS
in the 412 patients treated with ABVD or equivalent regimens. The
5-year FFS for patients with cHD in which HRS cells exhibited strong
versus weak versus undetectable BCL-2 expression was 70%, 78%, and
89%, respectively (P < .0007 by log-rank test; Figure
4A). For those patients with stage III or
IV disease, the corresponding FFS was 54%, 69%, 82%, respectively
(P = .002 by log-rank test; Figure 4B). Similarly, OS at 5 years for this group of patients in which HRS cells expressed BCL-2
strongly versus weakly, or were negative was 83%, 92%, and 96%,
respectively (P = .001 by log-rank test).
Univariate and multivariate analysis Univariate statistical analysis for FFS confirmed the significance of most established clinical and laboratory prognostic factors (Table 5). Serum LDH levels, serum2-microglobulin levels, anemia, and serum albumin levels
were analyzed using the appropriate lower or higher limits as cutoffs.
Albumin levels with a cutoff of 4.0 g/dL (which is higher than lower
normal level) and hemoglobin levels at the cutoff of 10.5 g/dL (which
is lower than lower normal limit) as used by the IPS5 were
also prognostic in our patient population (data not shown).
Multivariate analysis using the Cox proportional hazard model revealed
that BCL-2 expression in HRS cells was an independent prognostic
factor. The other factors that entered the final model, along with
BCL-2 expression, were age 45 years or older, Ann Arbor stage IV, low
serum albumin level, and high serum LDH level (Table 6 and Figure
5). Identical results were obtained
using stepwise forward and backward variable selection with the Cox
proportional hazards model (data not shown). The variables and their
cutoffs as used by Hasenclever and Diehl in the IPS5 were
also tried in the multivariate analysis. Once BCL-2 was entered in the
model, it was not possible to enter hemoglobin levels (at the cutoff of
10.5 g/dL), albumin levels (at the cutoff of 4.0 g/dL), leukocytosis, lymphocytopenia, and sex (data not shown). The combination of BCL-2 expression with these 4 adverse clinical features identified 68 (22%) of 314 patients of all stages who have 3 or more adverse factors
and 31 of them (10%) who have a 5-year FFS lower than 60% (Figure
5A). If the analysis is restricted to patients with stage III and IV
disease, the combination of all 5 adverse prognostic factors revealed
that 54 of 151 patients (36% of the population) had 3 or more adverse
prognostic factors and 27 of them (18%) had 5-year FFS lower than 60%
(Figure 5B). The model developed for FFS also identified groups of
patients with statistically different OS (P < .0001 by
log-rank test).
We report that BCL-2 is expressed by HRS cells in 61% of all patients with cHD and its expression is significantly more frequent in nodular sclerosis than mixed cellularity histology. The expression of BCL-2 in HRS cells is associated with inferior FFS and OS in patients treated with ABVD or equivalent regimens. Similarly, the intensity of BCL-2 expression is associated with statistically significant different FFS and OS. This conclusion is based on analysis of 707 patients derived from an international database that included 1695 previously untreated patients with biopsy-proven cHD. This study group was selected on the basis of the availability of archival pretreatment tissue for determination of BCL-2 expression. Statistical analysis showed that the presenting clinical and laboratory features of patients with known versus unknown BCL-2 expression were very similar. Therefore, we considered the group with known BCL-2 expression by HRS cells to be representative of the entire patient population. For the purpose of statistical analysis, we considered tumors with any HRS cells that express BCL-2 to be positive. This choice was based on the biologic assumption that even a few BCL-2+ HRS cells might survive chemotherapy-induced apoptosis and cause a relapse. Thus, we avoided choosing any arbitrary percentage of positive HRS cells as a cutoff to define BCL-2 expression. This choice is further supported by the distribution of BCL-2+ HRS cells among tumors as shown in Figure 2B. Using these criteria, BCL-2 was expressed more frequently and more intensely in HRS cells of patients with nodular sclerosis than mixed cellularity histology. Expression of BCL-2 was also associated with age younger than 45 years, female sex, and stage II disease. These associations are expected because nodular sclerosis HD is more frequent in patients younger than 45 years, with female sex and stage II disease in our patient population (data not shown). Perhaps these associations can account for the similar FFS between nodular sclerosis and mixed cellularity histology, despite the more frequent BCL-2 expression in the former. For FFS, we considered as events only failure to control tumor, as was done in the generation of the IPS.5 However, for OS any deaths were considered as events, even after highly variable salvage therapy. BCL-2 expression by HRS cells of cHD was associated with significantly lower FFS and OS in all patients and in those treated with ABVD or equivalent regimens. This association was also significant for patients with either early or advanced Ann Arbor stages, and cannot be explained by an association of BCL-2 expression with high IPS as shown in Table 4. Because of the small patient numbers and highly variable radiotherapy ports and treatment cycles, it was not possible to meaningfully analyze patients treated only with radiotherapy, NOVP and radiotherapy, or a variable number of MOPP cycles with or without radiotherapy. For patients treated with ABVD or equivalent regimens, multivariate analysis demonstrated that BCL-2 expression by HRS cells in cHD was independently associated with inferior FFS (Table 6 and Figure 5). However, other factors contributed significantly to outcome. The combination of BCL-2 expression in HRS cells with age older than 45 years, stage IV, low serum albumin, and high serum LDH identifies 18% of patients with stage III or IV disease with 5-year FFS lower than 60%. Smolewski et al40 analyzed BCL-2 expression in HRS cells of 194 patients with HD, including patients with lymphocyte-predominant histology. Using a 10% cutoff for positivity, BCL-2 was expressed in 47% of tumors.40 Although the authors did not report FFS, their analysis for all patients who received variable initial and variable salvage therapy demonstrated that BCL-2 expression was associated with statistically inferior OS.40 In another study, using a cutoff of 25% for positivity, BCL-2 was more frequently expressed in HRS cells of those patients with nodular sclerosis HD who did not achieve CR.41 Single-cell polymerase chain reaction and immunohistochemical studies have shown that HRS cells express BCL-2 mRNA and protein without carrying the t(14;18).23-25 Although previous studies demonstrated the rare presence of t(14;18) or BCL2 gene rearrangements in HD,42-45 more refined analysis has revealed that these rearrangements are not present in HRS cells but in bystander small reactive B lymphocytes. The molecular basis underlying BCL-2 expression in HRS cells is not yet clarified, cannot be established by this study, and merits further investigation. BCL-2 expression has been detected frequently in aggressive non-Hodgkin lymphomas, occurs independently of the t(14;18), and is similarly associated with unfavorable prognosis.46-49 Therefore, it appears that expression of BCL-2 is associated with inferior clinical outcome in patients with either cHD or non-Hodgkin lymphoma. We conclude that BCL-2 is expressed in HRS cells in 61% of patients with cHD. In positive tumors, the majority of HRS cells express BCL-2 but the intensity of expression is variable. BCL-2 expression is an independent adverse prognostic factor that may contribute to the failure of primary therapy and also the inability to save these patients after relapse. Other prognostic factors, in addition to BCL-2 expression in HRS cells, also contribute to the inferior clinical outcome. Furthermore, our results suggest that modulation of BCL-2 function50-52 may have a future role in the treatment of cHD.
Submitted November 13, 2001; accepted August 2, 2002.
Supported in part by Cancer Center support grant CA-16672 to the University of Texas M. D. Anderson Cancer Center. G.Z.R. is a recipient of an Alexander S. Onassis Foundation scholarship.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Andreas H. Sarris, c/o George Z. Rassidakis, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 72, Houston, TX 77030; e-mail: gzrassidakis{at}mail.mdanderson.org.
1. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478-1484[Abstract]. 2. Straus DJ, Gaynor JJ, Myers J, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990;8:1173-1186[Abstract]. 3. Proctor SJ, Taylor P, Mackie MJ, et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Leuk Lymphoma. 1992;7(suppl):17-20[Medline] [Order article via Infotrieve]. 4. Ferme C, Bastion Y, Brice P, et al. Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study. Cancer. 1997;80:1124-1133[CrossRef][Medline] [Order article via Infotrieve].
5.
Hasenclever D, Diehl V.
A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on advanced Hodgkin's disease.
N Engl J Med.
1998;339:1506-1514
6.
Sarris AH, Kliche KO, Pethambaram P, et al.
Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.
Ann Oncol.
1999;10:433-440 7. Viviani S, Notti P, Bonfante V, Verderio P, Valagussa P, Bonadonna G. Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin's disease, the Milan Cancer Institute Experience. Medical Oncology. 2000;17:59-63[Medline] [Order article via Infotrieve]. 8. Bohlen H, Kessler M, Sextro M, Diehl V, Tesch H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol. 2000;79:110-113[CrossRef][Medline] [Order article via Infotrieve].
9.
Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al.
Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma.
Haematologica.
2001;86:274-281
10.
Nadali G, Tavecchia L, Zanolin E, et al.
Serum level of the soluble form of CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome.
Blood.
1998;91:3011-3016 11. Kuppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Ann Rev Immunol. 1998;16:471-493[CrossRef][Medline] [Order article via Infotrieve].
12.
Ohno T, Stribley JA, Wu G, Hinrichs SH, Weisenburger DD, Chan WC.
Clonality in nodular lymphocyte-predominant Hodgkin's disease [see comments].
N Engl J Med.
1997;337:459-465
13.
Kanzler H, Kuppers R, Hansmann ML, Rajewsky K.
Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells.
J Exp Med.
1996;184:1495-1505
14.
Marafioti T, Hummel M, Foss HD, et al.
Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription.
Blood.
2000;95:1443-1450
15.
Stein H, Marafioti T, Foss HD, et al.
Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription.
Blood.
2001;97:496-501
16.
Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM.
Cloning of the chromosome breakpoint of neoplastic B cells with the t(14; 18) chromosome translocation.
Science.
1984;226:1097-1099 17. McDonnell TJ, Deane N, Platt FM, et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989;57:79-88[CrossRef][Medline] [Order article via Infotrieve]. 18. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature. 1991;349:254-256[CrossRef][Medline] [Order article via Infotrieve].
19.
Adams JM, Cory S.
The Bcl-2 protein family: arbiters of cell survival.
Science.
1998;281:1322-1326 20. Doussis IA, Pezzella F, Lane DP, Gatter KC, Mason DY. An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin's disease. Am J Clin Pathol. 1993;99:663-667[Medline] [Order article via Infotrieve].
21.
Brousset P, Benharroch D, Krajewski S, et al.
Frequent expression of the cell death-inducing gene Bax in Reed-Sternberg cells of Hodgkin's disease.
Blood.
1996;87:2470-2475 22. Hell K, Lorenzen J, Fischer R, Hansmann ML. Hodgkin cells accumulate mRNA for bcl-2. Lab Invest. 1995;73:492-496[Medline] [Order article via Infotrieve]. 23. Bhagat SK, Medeiros LJ, Weiss LM, Wang J, Raffeld M, Stetler-Stevenson M. bcl-2 expression in Hodgkin's disease. Correlation with the t(14;18) translocation and Epstein-Barr virus. Am J Clin Pathol. 1993;99:604-608[Medline] [Order article via Infotrieve].
24.
Gravel S, Delsol G, Al Saati T.
Single-cell analysis of the t(14;18)(q32;q21) chromosomal translocation in Hodgkin's disease demonstrates the absence of this translocation in neoplastic Hodgkin and Reed-Sternberg cells.
Blood.
1998;91:2866-2874 25. Sarris AH, Jhanwar SC, Cabanillas F. Cytogenetics of Hodgkin's disease. In: Mauch PM,Armitage JO,Diehl V,Hoppe RT,Weiss LM, eds. Hodgkin's Disease. New York: Lippincott-Raven; 1999:195-212. 26. Stein H, Mann R, Delsol G, et al. Classical Hodgkin lymphoma. Tumours of Haematopoietic and Lymphoid Tissues. Pathology and genetics. In: Jaffe E,Harris N,Stein H,Vardiman J, eds. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001:244-253.
27.
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M.
Report of the Committee on Hodgkin's Disease Staging Classification.
Cancer Res.
1971;31:1860-1861
28.
Longo DL, Young RC, Wesley M, et al.
Twenty years of MOPP therapy for Hodgkin's disease.
J Clin Oncol.
1986;4:1295-1306 29. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252-259[CrossRef][Medline] [Order article via Infotrieve]. 30. Angelopoulou MK, Vassilakopoulos TP, Siakantaris MP, et al. EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease. Leuk Lymphoma. 2000;37:131-143[Medline] [Order article via Infotrieve]. 31. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med. 1986;104:739-746[Medline] [Order article via Infotrieve]. 32. Hagemeister FB, Fuller L, McLaughlin P, et al. NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis. Ann Oncol. 1992;4:87-90[Medline] [Order article via Infotrieve]. 33. Viviani S, Bonfante V, Santoro A, et al. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am. 1999;5:275-282[Medline] [Order article via Infotrieve].
34.
Viviani S, Bonadonna G, Santoro A, et al.
Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
J Clin Oncol.
1996;14:1421-1430
35.
Connors JM, Klimo P, Adams G, et al.
Treatment of advanced Hodgkin's disease with chemotherapy
36.
Rassidakis GZ, Sarris AH, Herling M, et al.
Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.
Am J Pathol.
2001;159:527-535 37. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:257-481. 38. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170[Medline] [Order article via Infotrieve]. 39. Cox DR. Regression models and life tables [with discussion]. J R Stat Soc B. 1972;34:187-220.
40.
Smolewski P, Robak T, Krykowski E, et al.
Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.
Clin Cancer Res.
2000;6:1150-1160 41. van Spronsen DJ, Peh SC, Vrints LW, van Imhoff GW, Poppema S. Clinical drug-resistant nodular sclerosing Hodgkin's lymphoma is associated with decreased bcl-2 expression in the surrounding lymphocytes and with increased bcl-2 expression in the Reed-Sternberg cells. Histopathology. 2000;37:420-426[CrossRef][Medline] [Order article via Infotrieve].
42.
Gupta RK, Whelan JS, Lister TA, Young BD, Bodmer JG.
Direct sequence analysis of the t(14;18) chromosomal translocation in Hodgkin's disease.
Blood.
1992;79:2084-2088 |
Top
Abstract
Introduction
HRS cells. The
small reactive lymphocytes stained positively for BCL-2 and served as
internal positive controls in all panels. Original magnifications
A, C, E, × 100; B, D, F, × 400.
indicates BCL-2+ cHD; 
, BCL-2
, weak BCL-2 expression; 
, 1 adverse feature; 
, 2 adverse features; 
comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
J Clin Oncol.
1997;15:1638-1645